11th IAS Conference on HIV Science (IAS 2021), Berlin, Germany, 18-21 July 2021

第 11 届 IAS HIV 科学会议 (IAS 2021)，德国柏林，2021 年 7 月 18-21 日

• 批准号: 10254560
• 负责人: Christopher C. Beyrer
• 金额: $ 75万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-09 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10254560
• 关键词: 2019-nCoV; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adherence; Adolescent and Young Adult; Adult; Affect; Africa; Africa South of the Sahara; Age; Aging; Antiviral Agents; Basic Science; Behavioral; Behavioral Sciences; Berlin; COVID-19; COVID-19 pandemic; COVID-19 vaccine; Caring; Child; Childhood; Chronic; Cities; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; Contraceptive Agents; Contraceptive methods; Counseling; Country; Coupled; Data; Development; Discrimination; Disease; Disease Progression; Disease remission; Eastern Europe; Emergency response; Ensure; Epidemic; Europe; Failure; Fatigue; Financial Support; Formulation; Fostering; Futility; Gays; Germany; HIV; HIV Vaccine Trials Network; HIV vaccine; HIV/TB; Health; Health Resources; Health Services Accessibility; Health system; Heart; Homophobia; Human; Human immunodeficiency virus test; Immunology; Incidence; Incidence Study; Infant; Infection; Injectable; Injecting drug user; Integrase Inhibitors; International AIDS; Interruption; Intervention; Knowledge; Leadership; Life; Minority; Modality; Morbidity - disease rate; Multi-Drug Resistance; Opiate Addiction; Outcome; Pathogenesis; Patients; Persons; Population; Positioning Attribute; Prevention; Prevention Research; Prevention approach; Prevention program; Preventive vaccine; Public Health; Recording of previous events; Regimen; Relative Risks; Reporting; Research; Research Personnel; Resources; Rights; Risk Reduction; SARS-CoV-2 infection; Safety; Science; Scientist; Social Sciences; Structure; Technology; Testing; Ukraine; Uncertainty; Update; Vaccines; Variant; Viral hepatitis; Virus Diseases; War; Woman; Work; base; body system; clinical care; co-infection; community engagement; comorbidity; density; efficacy trial; implementation science; improved; innovation; insight; interdisciplinary collaboration; low and middle-income countries; marginalized population; men; men who have sex with men; mortality; multidisciplinary; novel; pandemic disease; patient oriented; person centered; pill; pre-exposure prophylaxis; precision medicine; preventive intervention; programs; public health emergency; racial and ethnic disparities; reproductive; response; social stigma; social structure; symposium; synergism; tool; transgender women; transmission process; transphobia; treatment program; virology; virtual; virtual delivery

Project Summary The scientific and public health response against HIV/AIDS in the past four decades has been remarkable and unprecedented. Yet HIV transmission continues in many populations at unacceptably high rates despite testing and treatment availability, largely driven by stigma and discrimination and other social and structural determinants. IAS 2021 will be the key global scientific convening to review progress against remaining challenges in controlling the epidemic. Significant new insights that are expected to be shared at IAS 2021 include basic work on virology, immunology and HIV pathogenesis with a continued focus on the functional cure/remission agenda. Clinical research in HIV is entering a new era of longer acting and injectable formulations which will be highlighted at IAS 2021, along with the remaining challenges of adherence, pill fatigue, and multi-drug resistant variants. Pediatric clinical care issues will be a further key topic where the advances in newer integrase inhibitor-based regimens for infants and children will be a primary focus. In the prevention field, the finding of superiority for long-acting injectable cabotegravir as PrEP marks the beginning of a new era, with further evidence expected in this regard at IAS 2021, along with early data on the co-formulations of long-acting injectables with other products for contraception, opioid dependence, and other health conditions. In the implementation science field innovative testing, prevention, treatment, and surveillance modalities will feature prominently at IAS 2021. Finally, the COVID-19 pandemic is expected to be among the defining themes across all scientific tracks against the background of treatment interruptions worldwide and the many remaining uncertainties regarding HIV/SARS- CoV-2 interactions. While the IAS is making parallel provisions for shifting to a fully virtual delivery format if mandated by the state of the COVID-19 pandemic, IAS 2021 is planned to take place in Berlin from 18-21 July 2021, with a strong virtual presence to ensure broad access (expected attendance of 6,000 delegates). It will provide a critical platform for HIV science to re-convene in a country now characterized by a celebration of diversity and zero discrimination. Berlin is at the heart of Europe, with close connectivity to the most HIV-affected region in Europe—Central and Eastern Europe, in particular Ukraine, and the Russian Federation, where, in marked contrast to Germany, rights-based approaches to HIV programming are constantly challenged. Specific aims of IAS 2021 are to: 1. Accelerate basic science and clinical innovation for the development and application of person-centered, precision medicine for HIV, including pathogenesis, transmission, vaccines, remission and a functional cure. 2. Advance inter-disciplinary collaboration in clinical research to improve integrated care across all life stages and accelerate updates to treatment guidance especially for low and middle-income countries, infected children, persons with HIV, TB, viral hepatitis and COVID-19 infection; 3. Strengthen HIV prevention research to improve biomedical, behavioral and structural interventions and the integration of new tools, including long-acting injectable prevention technologies in prevention programs for those in need; 4. Advance core components of the implementation science agenda across the HIV prevention-to-care cascade in the COVID-19 era, including aspects of integration and approaches for meaningful community engagement and resourcing health systems; 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, other diseases, homophobia, transphobia, and ethnic and racial disparities. The scientific program will consist of four tracks: Track A – Basic Science; Track B – Clinical Science; Track C – Prevention Science; and Track D – Social, Behavioral, and Implementation Science. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives, and bridging sessions will cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to increased remote-access options.

项目概要 过去四十年中针对艾滋病毒/艾滋病的科学和公共卫生应对措施非常出色， 然而，尽管进行了检测，艾滋病毒在许多人群中的传播率仍然高得令人无法接受。 和治疗的可获得性，很大程度上是由耻辱和歧视以及其他社会和结构性因素驱动的 2021 年 IAS 将成为审查剩余进展的重要全球科学会议。 疫情防控面临挑战。 预计将在 2021 年 IAS 上分享的重要新见解包括病毒学、免疫学的基础工作 和艾滋病毒发病机制，并继续关注艾滋病毒的功能性治愈/缓解议程。 正在进入长效和注射制剂的新时代，这将在 2021 年 IAS 上得到强调，同时 剩下的挑战包括依从性、药物疲劳和多重耐药变异。 问题将是一个进一步的关键主题，其中基于新整合酶抑制剂的婴儿和儿童治疗方案的进展 儿童将成为预防领域的主要关注点，寻找长效注射剂的优越性。 卡博特韦作为 PrEP 标志着一个新时代的开始，IAS 预计将在这方面提供进一步的证据 2021 年，以及长效注射剂与其他产品的联合配方的早期数据 避孕、阿片类药物依赖和其他健康状况在实施科学领域的创新。 检测、预防、治疗和监测方式将在 2021 年 IAS 上占据显着位置。最后， 预计 COVID-19 大流行将成为所有科学领域的决定性主题之一 全球治疗中断的背景以及有关 HIV/SARS 的许多剩余不确定性 CoV-2 相互作用。 虽然 IAS 正在制定并行规定，以便在国家强制要求的情况下转向完全虚拟的交付格式 鉴于 COVID-19 大流行，IAS 2021 计划于 2021 年 7 月 18 日至 21 日在柏林举行， 虚拟出席以确保广泛的访问（预计将有 6,000 名代表出席）。 艾滋病毒科学平台在一个现在以庆祝多样性和零为特征的国家重新召开 柏林位于欧洲的中心，与艾滋病毒感染最严重的地区有着密切的联系。 欧洲——中欧和东欧，特别是乌克兰和俄罗斯联邦，其中标有 与德国不同的是，基于权利的艾滋病毒规划方法不断受到挑战。 IAS 2021 的具体目标是： 1. 加快基础科学和临床创新，促进以人为本、 HIV 精准医学，包括发病机制、传播、疫苗、缓解和功能性治愈。 2. 推进临床研究跨学科合作，改善生命各阶段的综合护理 并加快更新治疗指南，特别是针对低收入和中等收入国家、感染者的治疗指南 儿童、艾滋病毒、结核病、病毒性肝炎和 COVID-19 感染者； 3. 加强艾滋病毒预防研究，改进生物医学、行为和结构干预措施以及 将新工具（包括长效注射预防技术）纳入预防方案 有需要的人； 4. 推进艾滋病毒预防到护理级联实施科学议程的核心组成部分 在 COVID-19 时代，包括整合方面和有意义社区的方法 卫生系统的参与和资源配置； 5. 解决关键和边缘人群中的艾滋病毒脆弱性和疾病进展的决定因素， 包括减少耻辱和歧视的新颖干预措施和科学，包括 艾滋病毒、其他疾病、恐同症、跨性别者恐惧症以及民族和种族差异的交叉耻辱。 科学课程将包括四个方向：A 方向 - 基础科学；B 方向 - 临床科学； – 预防科学；以及D轨道 – 社会、行为和实施科学。 全体会议的讨论也将科学轨道与社区和领导力的观点联系起来， 桥接课程将跨越至少两个轨道，为多学科提供机会 青年研究人员、基础科学家和非相关领域研究人员的参与。 将通过积极征求相关科学知识并提供 除了增加远程访问选项之外，还提供具体的财政支持。